© 2002 by Oxford University Press
Journal of the National Cancer Institute, Vol. 94, No. 24, 1863-1877,
December 18, 2002
© 2002 Oxford University Press
ARTICLE |
Effect of RNA Silencing of Polo-Like Kinase-1 (PLK1) on Apoptosis and Spindle Formation in Human Cancer Cells
Affiliation of authors: B. Spänkuch-Schmitt, M. Kaufmann, K. Strebhardt (Department of Obstetrics and Gynecology, School of Medicine), J. Bereiter-Hahn (Department of Biology), J. W. Goethe-University, Frankfurt, Germany.
Correspondence to: Prof. Dr. K. Strebhardt, Department of Obstetrics and Gynecology, J. W. Goethe-University, Theodor-Stern-Kai 7, D-60590 Frankfurt, Germany (e-mail: Strebhardt{at}em.uni-frankfurt.de).
Background: Expression of polo-like kinase-1 (PLK1), which has several functions in mitotic progression, is elevated in a broad range of human tumors. To investigate the role of PLK1 in neoplastic proliferation, we used the technique of RNA interference. Methods: Cells from several different cancer cell lines (MCF-7 breast cancer cells, HeLa S3 cervical cancer cells, SW-480 colon cancer cells, and A549 lung cancer cells) were transfected with small interfering (si) RNAs targeted against the human PLK1 or lamin genes. Northern and western blot analyses were used to examine PLK1 gene expression in transfected cancer cells and normal cells (human mammary epithelial cells [HMECs]). The phenotype, proliferation, and cell cycle distribution of cells transfected with siRNAs were also monitored by fluorescence microscopy and fluorescence-activated cell sorting analysis. Results: All cancer cell lines transfected with low doses of siRNAs targeted to PLK1 had greatly decreased levels of PLK1 mRNA and protein. siRNA4, which had the strongest inhibitory effect, reduced PLK1 mRNA in MCF-7 cells by 70% and PLK1 protein in MCF-7 cells by 95% 24 hours after transfection. Cell proliferation was reduced by between 66% and 99% 48 hours after transfection, and apoptosis was increased from 1%–5% to 13%–50% in transfected cells. Transfected SW-480 cells were mitotically arrested, and their centrosomes had lost the ability to nucleate microtubules. HMECs took up siRNAs less efficiently than cancer cells, and transfection with siRNAs targeted to PLK1 did not inhibit their proliferation. Conclusions: PLK1 function appears to be essential for centrosome-mediated microtubule events and, consequently, for spindle assembly. siRNAs targeted against human PLK1 may be valuable tools as antiproliferative agents that display activity against a broad spectrum of neoplastic cells at very low doses.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  W. Gong, Y. Ren, H. Zhou, Y. Wang, S. Kang, and T. Li siDRM: an effective and generally applicable online siRNA design tool Bioinformatics, October 15, 2008; 24(20): 2405 - 2406. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Kawata, E. Ashihara, S. Kimura, K. Takenaka, K. Sato, R. Tanaka, A. Yokota, Y. Kamitsuji, M. Takeuchi, J. Kuroda, et al. Administration of PLK-1 small interfering RNA with atelocollagen prevents the growth of liver metastases of lung cancer Mol. Cancer Ther., September 1, 2008; 7(9): 2904 - 2912. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. L Schmit and N. Ahmad Regulation of Mitosis via Mitotic Kinases: New Opportunities for Cancer Management Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 133 - 150. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Koida, T. Ozaki, H. Yamamoto, S. Ono, T. Koda, K. Ando, R. Okoshi, T. Kamijo, K. Omura, and A. Nakagawara Inhibitory Role of Plk1 in the Regulation of p73-dependent Apoptosis through Physical Interaction and Phosphorylation J. Biol. Chem., March 28, 2008; 283(13): 8555 - 8563. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. L. Schmit and N. Ahmad Regulation of mitosis via mitotic kinases: new opportunities for cancer management Mol. Cancer Ther., July 1, 2007; 6(7): 1920 - 1931. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. E. Morgan-Lappe, L. A. Tucker, X. Huang, Q. Zhang, A. V. Sarthy, D. Zakula, L. Vernetti, M. Schurdak, J. Wang, and S. W. Fesik Identification of Ras-Related Nuclear Protein, Targeting Protein for Xenopus Kinesin-like Protein 2, and Stearoyl-CoA Desaturase 1 as Promising Cancer Targets from an RNAi-Based Screen Cancer Res., May 1, 2007; 67(9): 4390 - 4398. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. J. Lansing, R. T. McConnell, D. R. Duckett, G. M. Spehar, V. B. Knick, D. F. Hassler, N. Noro, M. Furuta, K. A. Emmitte, T. M. Gilmer, et al. In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1 Mol. Cancer Ther., February 1, 2007; 6(2): 450 - 459. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kappel, Y. Matthess, B. Zimmer, M. Kaufmann, and K. Strebhardt Tumor inhibition by genomically integrated inducible RNAi-cassettes Nucleic Acids Res., September 11, 2006; 34(16): 4527 - 4536. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. L. Garland, C. Taylor, D. L. Pilkington, J. L. Cohen, and D. D. Von Hoff A Phase I Pharmacokinetic Study of HMN-214, a Novel Oral Stilbene Derivative with Polo-Like Kinase-1-Interacting Properties, in Patients with Advanced Solid Tumors Clin. Cancer Res., September 1, 2006; 12(17): 5182 - 5189. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Spankuch, S. Heim, E. Kurunci-Csacsko, C. Lindenau, J. Yuan, M. Kaufmann, and K. Strebhardt Down-regulation of Polo-like Kinase 1 Elevates Drug Sensitivity of Breast Cancer Cells In vitro and In vivo Cancer Res., June 1, 2006; 66(11): 5836 - 5846. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Liu, M. Lei, and R. L. Erikson Normal cells, but not cancer cells, survive severe plk1 depletion. Mol. Cell. Biol., March 1, 2006; 26(6): 2093 - 2108. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Eckerdt, J. Yuan, K. Saxena, B. Martin, S. Kappel, C. Lindenau, A. Kramer, S. Naumann, S. Daum, G. Fischer, et al. Polo-like Kinase 1-mediated Phosphorylation Stabilizes Pin1 by Inhibiting Its Ubiquitination in Human Cells J. Biol. Chem., November 4, 2005; 280(44): 36575 - 36583. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Liu, C.-Y. Lin, M. Lei, S. Yan, T. Zhou, and R. L. Erikson CCT Chaperonin Complex Is Required for the Biogenesis of Functional Plk1 Mol. Cell. Biol., June 15, 2005; 25(12): 4993 - 5010. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Guan, P. Tapang, J. D. Leverson, D. Albert, V. L. Giranda, and Y. Luo Small Interfering RNA-Mediated Polo-Like Kinase 1 Depletion Preferentially Reduces the Survival of p53-Defective, Oncogenic Transformed Cells and Inhibits Tumor Growth in Animals Cancer Res., April 1, 2005; 65(7): 2698 - 2704. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. W. Gunawardena, H. Siddiqui, D. A. Solomon, C. N. Mayhew, J. Held, S. P. Angus, and E. S. Knudsen Hierarchical Requirement of SWI/SNF in Retinoblastoma Tumor Suppressor-mediated Repression of Plk1 J. Biol. Chem., July 9, 2004; 279(28): 29278 - 29285. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Ando, T. Ozaki, H. Yamamoto, K. Furuya, M. Hosoda, S. Hayashi, M. Fukuzawa, and A. Nakagawara Polo-like Kinase 1 (Plk1) Inhibits p53 Function by Physical Interaction and Phosphorylation J. Biol. Chem., June 11, 2004; 279(24): 25549 - 25561. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Spankuch, Y. Matthess, R. Knecht, B. Zimmer, M. Kaufmann, and K. Strebhardt Cancer Inhibition in Nude Mice After Systemic Application of U6 Promoter-Driven Short Hairpin RNAs Against PLK1 J Natl Cancer Inst, June 2, 2004; 96(11): 862 - 872. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Moshe, J. Boulaire, M. Pagano, and A. Hershko Role of Polo-like kinase in the degradation of early mitotic inhibitor 1, a regulator of the anaphase promoting complex/cyclosome PNAS, May 25, 2004; 101(21): 7937 - 7942. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. S. Kho, Z. Wang, L. Zhuang, Y. Li, J.-L. Chew, H.-H. Ng, E. T. Liu, and Q. Yu p53-regulated Transcriptional Program Associated with Genotoxic Stress-induced Apoptosis J. Biol. Chem., May 14, 2004; 279(20): 21183 - 21192. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Gray Jr, D. J. Bearss, H. Han, R. Nagle, M.-S. Tsao, N. Dean, and D. D. Von Hoff Identification of human polo-like kinase 1 as a potential therapeutic target in pancreatic cancer Mol. Cancer Ther., May 1, 2004; 3(5): 641 - 646. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. AHMAD Polo-like kinase (Plk) 1: a novel target for the treatment of prostate cancer FASEB J, January 1, 2004; 18(1): 5 - 7. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Liu and R. L. Erikson Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells PNAS, May 13, 2003; 100(10): 5789 - 5794. [Abstract] [Full Text] [PDF]
|
|